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BNIP3 supports melanoma cell migration and
vasculogenic mimicry by orchestrating the
actin cytoskeleton
H Maes1, S Van Eygen1, DV Krysko2,3, P Vandenabeele2,3, K Nys1, K Rillaerts1, AD Garg1, T Verfaillie1 and P Agostinis*,1
BNIP3 is an atypical BH3-only member of the BCL-2 family of proteins with reported pro-death as well as pro-autophagic and
cytoprotective functions, depending on the type of stress and cellular context. In line with this, the role of BNIP3 in cancer is
highly controversial and increased BNIP3 levels in cancer patients have been linked with both good as well as poor prognosis.
In this study, using small hairpin RNA (shRNA) lentiviral transduction to stably knockdown BNIP3 (BNIP3-shRNA) expression
levels in melanoma cells, we show that BNIP3 supports cancer cell survival and long-term clonogenic growth. Although BNIP3-
shRNA increased mitochondrial mass and baseline levels of reactive oxygen species production, which are features associated
with aggressive cancer cell behavior, it also prevented cell migration and completely abolished the ability to form a tubular-like
network on matrigel, a hallmark of vasculogenic mimicry (VM). We found that this attenuated aggressive behavior of these
melanoma cells was underscored by severe changes in cell morphology and remodeling of the actin cytoskeleton associated
with loss of BNIP3. Indeed, BNIP3-silenced melanoma cells displayed enhanced formation of actin stress fibers and membrane
ruffles, while lamellopodial protrusions and filopodia, tight junctions and adherens junctions were reduced. Moreover, loss of
BNIP3 resulted in re-organization of focal adhesion sites associated with increased levels of phosphorylated focal adhesion
kinase. Remarkably, BNIP3 silencing led to a drop of the protein levels of the integrin-associated protein CD47 and its
downstream signaling effectors Rac1 and Cdc42. These observations underscore that BNIP3 is required to maintain steady-state
levels of intracellular complexes orchestrating the plasticity of the actin cytoskeleton, which is integral to cell migration and
other vital processes stimulating cancer progression. All together these results unveil an unprecedented pro-tumorigenic role of
BNIP3 driving melanoma cell’s aggressive features, like migration and VM.
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B-cell lymphoma 2 (BCL-2) 19 kDa interacting protein 3
(BNIP3) is a BH3-only protein that belongs to the BCL-2
family of cell death regulators, with an emerging role in various
pathological conditions, including cancer. BNIP3 is highly
upregulated under hypoxia through the hypoxia inducible
factor (HIF-1), although HIF-1-independent transcriptional
mechanisms and post-transcriptional mechanisms also con-
tribute to the regulation of BNIP3 expression in different cells
and tissues.1 BNIP3 is an atypical BH3-only protein since it
does not interact with anti-apoptotic BCL-2 family members
via its BH3 domain but through its C-terminal transmembrane
domain. The latter is also required for its insertion in
mitochondrial membranes during cell death induction2 relying
on both caspase-dependent3 as well as independent4
mechanisms. Besides these pro-death functions, BNIP3 also
mediates pro-survival autophagy induction.1,5 Indeed BNIP3
regulates mitochondrial fission and turnover through mito-
phagy, by directly binding to both mitochondria and the
autophagosomal protein LC3, thereby anchoring damaged/
superfluousmitochondria to the autophagymachinery.1 In line
with this, BNIP3 has been shown to modulate mitochondrial
mass and mitochondrial fitness in cardiac myocytes,1
fibroblasts6 and in the liver.7 Given the main pro-survival
role of autophagy, it is not surprising that in several other
reports BNIP3 expression has been linked to enhanced cell
viability.8–10 Moreover, BNIP3 itself can act as a transcrip-
tional repressor of death receptor-511 and apoptosis-inducing
factor,12 supporting a pro-survival role of BNIP3 through
mechanisms that are still incompletely understood but which
are independent of its mitochondrial targeting.
BNIP3 is overexpressed in various tumors and at different
stages of tumor progression.13,14 However, consistent with a
context-dependent role in cell death regulation, both tumor
suppressor and tumor promoter roles have been described for
BNIP3. For example, in certain cancer types like laryngeal
cancer15 and gastric cancer,16 low BNIP3 levels have been
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correlated with poor prognostic features and resistance to
therapy. Opposite to this, increased expression of BNIP3 in
hypoxic tumors caused by the transcriptional activation of
HIF-117 or downregulation of tumor suppressor pathways, like
miR145,18 correlated with accelerated tumor growth and
unfavorable prognosis in cancer patients.13
Thus although the latter studies highlight an important role
for BNIP3 in carcinogenesis, there is still a considerable
debate regarding the cellular processes and mechanisms
regulated by this atypical BH3-only protein in cancer cells.
Moreover, how BNIP3 modulates cancer cell progression and
dissemination is largely unknown.
Using melanoma as cellular model, here we show that
BNIP3 has an essential role in the maintenance of the actin
cytoskeletal organization and focal adhesion (FA) complexes
regulating melanoma cell’s migration and vasculogenic
mimicry (VM). These data disclose a previously unknown
mechanism by which BNIP3 supports melanoma cell’s
plasticity and aggressiveness.
Results
BNIP3 in melanoma is pro-survival and required for
long-term clonogenic growth. The expression of HIF-1
responsive genes, including BNIP3, has been shown to be
elevated in malignant melanoma as a result of a constitutive
HIF-1 activity harbored by these cancer cells even in
oxygenated areas of the tumors.19 Therefore, we set out to
delineate the role of BNIP3 in melanoma cell’s behavior, by
interfering with the baseline expression of BNIP3. To this
end, we stably knocked down BNIP3 expression by small
hairpin RNA (shRNA) in murine (B16-F10) and human
(A375m) metastatic melanoma cell lines, which resulted in
a significant decrease in the BNIP3 protein levels (Figure 1a,
Supplementary Figure S1A) as compared with control empty
vector-transduced cells. Since BNIP3 is an atypical BH3-only
protein with a contextual role in cancer cell death, we first
tested the effects of BNIP3 knockdown (KD) on melanoma
survival and long-term clonogenic growth. BNIP3-silenced
B16-F10 melanoma cells displayed increased spontaneous
cell death, identified as propidium iodide (PI)-positive cells,
although this process became relevant only at later time
points (i.e. 48–72 h) (Figure 1b). Notably, BNIP3 KD almost
completely abrogated melanoma’s long-term clonogenic
growth (Figure 1c, Supplementary Figure S1B), underscoring
its essential pro-survival role. Since BNIP3 has been
implicated in autophagy regulation, mitochondrial turnover
and redox regulation,20,21 we analyzed changes in the
formation of the autophagosome-associated pro-autophagic
LC3II, mitochondrial mass and levels of reactive oxygen
species (ROS) in controls and BNIP3-silenced melanoma
cells. LC3I conversion into LC3II was significantly reduced in
BNIP3-shRNA cells (Figure 2a, Supplementary Figure S1C),
indicating that BNIP3 regulates autophagosome formation,
as shown in previous studies.8,22 Loss of BNIP3 caused
an increase in the cellular ROS levels (Figure 2b,
Supplementary Figure S1D) along with a two-fold increase
in mitochondrial mass, as measured by mitochondrial DNA
content (Figure 2c) and Mitotracker staining (Figure 2d). In
addition, immunocytochemistry with anti-TOMM20 antibody
(Figure 2e), revealed a dense and disorganized mitochon-
drial network in BNIP3 knocked down cells.
Together, these results implicate BNIP3 in the autophagic
degradation of ROS-producing mitochondria and underscore
that basal constitutive levels of BNIP3 have an intrinsic
pro-survival role in melanoma cells.
BNIP3 promotes melanoma cell migration and VM.
Important characteristics of the plasticity and aggressiveness
of melanoma cells are the ability to migrate and participate in
the de novo formation of a functional vasculature network,
through a process known as VM. VM is thought to foster
cancer progression by contributing to the delivery of nutrient
supply to starved tumors and favor cancer cell dissemina-
tion.23,24 Emerging evidence indicates that both cancer cell
migration and VM are processes positively modulated by
ROS.25–27 Since BNIP3 silencing increased the levels of
intracellular ROS, we next analyzed the migratory ability of
BNIP3-shRNA transduced cells by monitoring wound healing
closure as a function of time (during 0–18 h). BNIP3 KD
decreased melanoma cell migration as compared with
control cells (Figure 3a, Supplementary Figure S2A) in the
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Figure 1 BNIP3 is required to maintain clonogenic growth of melanoma cells. (a) Confirmation of effective BNIP3 KD in control and BNIP3 shRNA transduced B16-F10
cells on protein level (24 h after cell plating). A representative western blot (n¼ 6) probed with anti-BNIP3 antibody and quantification below is shown. Actin is used as a
loading control. Statistical analysis was performed as described in the materials and methods section. (b) The effect of BNIP3 silencing on spontaneous cell death determined
by PI exclusion. Graph shows the percentage of dead cells (PI-positive) of control and BNIP3 KD conditions as a function of time after B16-F10 cell plating (12, 24 and 48 h)
(n¼ 3). (c) Representative images (n¼ 3) showing clonogenic expansion of control and BNIP3 silenced B16-F10 cells. Photos were taken 10 days after seeding of the cells
as a diluted single cell suspension
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wound-healing assay, which measures directional cell move-
ment in 2D. The addition of the antioxidant N-acetylcysteine
(NAC) reduced the migration of control melanoma cells and it
further aggravated the effect of BNIP3 KD (Supplementary
Figure S2B) in line with previous reports indicating that ROS
promote cell migration.28 Since loss of BNIP3 increased
baseline ROS production (Figure 2b) over controls, these
results also indicate that the reduced migratory capacity of
the untreated BNIP3 silenced melanoma cells relies on
mechanisms that are ROS independent.
A well-established hallmark of VM is the ability of
established cancer cells to form tube-like structures resem-
bling those formed by endothelial cells, when seeded on
three-dimensional (3D) matrices of collagen I.29 When we
assessed the capacity of melanoma cells to mimic a
vasculature network on BD Matrigel, we found that control
melanoma cells were able to form several tubular structures,
which although less structured, resembled those formed by
endothelial cells (Figure 3b, Supplementary Figure S2C). In
contrast, BNIP3 KD completely abrogated the ability of
melanoma cells to form capillary structures (Figure 3b,
Supplementary Figure S2C). Strikingly, BNIP3-silenced mel-
anoma cells collapsed in clusters formed of living cell
aggregates (Figure 3b) and again, reducing ROS levels did
not rescue this phenotype (Supplementary Figure S2D). It
should also be noted that these BNIP3-mediated effects were
not due to increased spontaneous cell death caused by loss of
BNIP3 expression, sincewithin the time frame of these assays
(i.e. 12 h), BNIP3 KD had minimal impact on melanoma
viability as measured by PI exclusion (Figure 1b).
In all, our data indicate that BNIP3 modulates melanoma
cell migration and is essential to induce VM.
BNIP3 is required to maintain cellular architecture and
cytoskeletal structures. Light microscopy analysis of
BNIP3-silenced melanoma cells, revealed that loss of BNIP3
in melanoma cells had a striking effect on cellular morpho-
logy. BNIP3-shRNA expressing B16-F10 melanoma cells
displayed a flat shape and an increased cell and nuclear size
as compared with control cells (Figure 4a, quantified in
Figures 4b and c). Actin filaments provide vital structural
support for cellular shape and polymerization of actin at the
leading edge is a fundamental process driving cell migra-
tion.30 Hence we visualized the actin cytoskeleton with the
high-affinity F-actin probe Alexa-488 labeled Phalloidin,
which stains polymerized F-actin proteins. Although in
control melanoma cells Phalloidin staining was mainly
localized at the cell edges, KD of BNIP3 increased F-actin
staining and caused the formation of bundles of polymerized
actin filaments (stress fibers) extending from the cell surface
through the cytoplasm (Figures 4d and e, Supplementary
Figure S3A). Interestingly, this stress fiber pattern has been
reported before for non-motile cells, displaying stress fibers
that are usually thicker and relatively stable, while in highly
motile cells stress fibers are fewer, thinner and more
dynamic.31 To further examine the BNIP3-mediated effect
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Figure 2 BNIP3 modulates autophagic degradation of mitochondria and ROS signaling in melanoma. (a) The effect of BNIP3 KD on basal cellular LC3I to LC3II
conversion in B16-F10 cells was determined by western blot (24 h after cell plating). A representative western blot (n¼ 7) probed with anti-LC3 antibody of control and BNIP3
KD conditions and quantifications are shown. Actin is used as a loading control. (b) Assessment of the effect of BNIP3 KD on cellular ROS levels in B16-F10 cells (24 h after
cell plating). Cellular fluorescence (green) is shown for control and BNIP3 KD conditions after incubation of the cells with CM-H2DCFDA (10 mM) for 30min (n¼ 6).
(c) Analysis of the mitochondrial DNA content of control and BNIP3 KD B16-F10 cells assessed as the ratio of mitochondrial (LPL)/ nuclear (ND1) DNA copy numbers (n¼ 5).
(d) Assessment of the effect of BNIP3 KD on cellular Mitotracker uptake in B16-F10 cells (24 h after cell plating). Cellular fluorescence (deep red) is shown for control and
BNIP3 KD conditions after incubation of the cells with Mitotracker (25 nM) for 30min (n¼ 3) and (e) representative confocal images (n¼ 3, five pictures per condition) of
control and BNIP3 KD B16-F10 cells (24 h after cell plating), after immunostaining for TOMM20 and the nuclear dye DAPI, scale bars represent 10 mM
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on the architecture of the actin cytoskeleton, we plated
melanoma cells at low density in order to be able to analyze
the formation of lamellipodia, filopodia and membrane ruffles
(Figures 4e and f). B16-F10 cells expressing BNIP3-shRNA
displayed a reduced number of lamellipodia (arrows
Figure 4e) and filopodia (arrows Figure 4f). In contrast,
BNIP3-shRNA expressing melanoma cells also showed
increased membrane ruffles (arrowheads Figure 4e,
Supplementary Figure S3A), which are compartments where
actin filament reorganization occurs. Interestingly, reduced
lamellipodia persistence and adhesion have been shown to
correlate with increased ruffle formation and with impaired
cell migration.32 The major cytoskeletal features elicited by
the silencing of BNIP3 in melanoma cells could not be
reversed by the presence of NAC (Supplementary Figure
S3B), suggesting that the underlying mechanism is largely
ROS independent. Remarkably, this BNIP3-mediated cytos-
keletal phenotype was not mimicked by silencing the
essential autophagy gene Atg5 (Supplementary Figure
S3C,D) in melanoma cells, thus indicating that defects in
the core autophagy machinery are not sufficient to explain
the dramatic changes in the cytoskeletal architecture caused
by loss of BNIP3 expression.
Collectively, our results indicate that BNIP3 regulates
cellular architecture and organization of the actin
cytoskeleton.
BNIP3 modulates the organization of FA complex sites.
Given the major function played by BNIP3 in the main-
tenance of the actin cytoskeleton and cell migration, we then
assessed the impact of loss of BNIP3 on FAs. FAs are
dynamic signaling structures that anchor the actin cytoske-
leton to the extracellular matrix (ECM) via integrins and their
assembly and disassembly are chiefly regulated by focal
adhesion kinase (FAK). Therefore, we focused on the protein
levels and subcellular localization of integrin av, which is
present in FAs and regulates adhesion strength,33 phos-
phorylated/active FAK (P-FAK) and vinculin, a FA protein
linking integrins with the actin cytoskeleton.34
Immunoblotting analysis revealed that BNIP3 KD signifi-
cantly increased the amount of integrin av (Figure 5a).
Interestingly, this was associated with a clustering of integrin
av at the cell edges and in a fiber-like pattern within the cell
body (Figure 5d). Moreover, KD of BNIP3 increased the level
of vinculin and P-FAK signal, as monitored with the specific
P-Y397 antibody recognizing the pool of activated FAK that
becomes autophosphorylated upon integrin clustering and FA
assembly (Figures 5b and c).35 Immunofluorescence analysis
revealed that in BNIP3-shRNA expressing melanoma cells,
P-FAK was clustered together at the edges of the membrane
ruffles, whereas in control cells P-FAK located in small foci
within lamellipodia and filopodia (Figure 5e), as typically found
in motile cells.35 Furthermore, co-staining for vinculin and
Phalloidin showed that in contrast to control cells, in BNIP3-
silenced cells the focal complexes clustered together at the
tips of the membrane ruffles, but also in the cell body and their
size was markedly increased (Figure 5f), suggesting an
imbalance in the dynamics of FA formation and disassembly.
Interestingly, although P-FAK modulates FA complex assem-
bly, FA disassembly has been reported to require depho-
sphorylation of P-FAK and dynamin-dependent integrin
endocytosis.36,37
In all, these results further confirm that reducing the basal
levels of BNIP3 in melanoma cells causes alterations in the
architecture and plasticity of the cytoskeleton and cell
attachment.
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Figure 3 BNIP3 promotes melanoma cell migration and VM. (a) Two-dimensional cell migration of control versus BNIP3 KD B16-F10 cells. Representative images (n¼ 3)
of the scratch at indicated time points and quantification of the wound area (size wound at Tx/size wound at T0) are shown, arrows indicate the wound area, scale bars
represent 400mm. (b) The ability of the B16-F10 cells to form a vascular-like network was assessed by plating the cells on growth factor reduced Matrigel. Representative
images (n¼ 4) 16 h after cell seeding and quantification are shown of control and BNIP3 KD cells, HUVEC were used as a positive control, scale bars represent 200mm
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BNIP3 modulates Rac1 and Cdc42, which support the
VM phenotype. Since BNIP3-silenced cells displayed dra-
matic changes in their cytoskeletal organization and reduced
motility, we next evaluated possible BNIP3 modulators
located in regions of membrane dynamics. Important
mediators of focal complex dynamics, migration and vascular
tube formation are the Rho-family of GTPases, Rac1 (RAS-
related C3 botulinum toxin substrate 1) and Cdc42.38–40
Cdc42 and Rac1 are crucial for filopodia and lamellipodia
formation, respectively, and for functional cell–cell junctions
and cell–ECM contact.41 Since their disturbed expression/
activity could contribute to the reduced migratory and blunted
VM phenotype of the BNIP3-silenced cells, we investigated
their involvement in BNIP3-modulated processes. Western
blot analysis revealed that the protein level of Rac1 as well as
Cdc42 was reduced in cells where BNIP3 was knocked down
(Figure 6a). Moreover, BNIP3 silencing also affected the
activation status of Rac1 and Cdc42 as measured by p21-
activated kinase (PAK)-based pull-down assays, since PAK
is a direct Cdc42 and Rac1 effector that associates only with
their GTP-bound forms (Figure 6b). Notably, baseline levels
of GTP bound Rac1 and Cdc42 in these B16-F10 melanoma
cells were particularly high,42 consistent with their elevated
motility and ability to form tubular networks. To address the
contribution of Cdc42 and Rac1 in BNIP3-modulated
processes, we inhibited the activity of these Rho family
GTPases and assessed their effects on the cytoskeleton,
migration and VM phenotype of control melanoma cells.
Counteracting either Rac1 activity with Ehop-01643 or Cdc42
activity with ML141,44 two small molecule inhibitors specific
for these Rho GTPase members, reduced the production of
lamellipodia (Ehop-016) or filopodia (ML141) protrusions in
B16-F10 cells (Supplementary Figures S4A and B), thus
confirming their inhibitory effects. Interestingly, Ehop-016 or
ML141 reduced cell migration (Figure 6c) and VM
(Figure 6d), when used separately and even more when
used in combination (Figures 6c and d), without affecting cell
viability (data not shown) within the time frame of the
experiments. Thus, a reduced expression/activity of these
cytoskeleton effectors in BNIP3 knocked down cells could
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Figure 4 BNIP3 is required to maintain cellular architecture and cytoskeletal structures. (a) Representative light microscopy images (n¼ 4, five pictures per experiment) of
control and BNIP3 KD B16-F10 cells (24 h after cell plating), scale bars represent 50 mm. (b) Cell surface area, quantified using ImageJ, of control and BNIP3 KD cells.
(c) Nuclear size, quantified using Image J, of control and BNIP3 KD cells. (d) Confocal microscopy analysis of the actin cytoskeleton of B16-F10 cells (24 h after cell plating)
using the high affinity actin-probe phalloidin-Alexa Flour 488 and the nuclear dye DAPI. Representative images (n¼ 5, five pictures per condition) of control versus BNIP3 KD
cells, scale bars represent 10mm. (e) Confocal microscopy analysis of the actin cytoskeleton using the high affinity actin-probe Phalloidin-Alexa Flour 488 and the nuclear dye
DAPI on low density cell culture of B16-F10 cells (24 h after cell plating). Representative images (n¼ 5, five pictures per condition) of control versus BNIP3 KD cells are shown.
Scale bars represent 10mm. Arrows indicate lamellipodia and arrowheads indicate membrane ruffles. (f) Higher magnification images of the staining in e to reveal cell
filopodia. Representative images (n¼ 5, five pictures per condition) and zoom of control and BNIP3 KD B16-F10 cells are shown, scale bar represents 10 mm, arrows indicate
filopodia
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contribute, at least in part, to the inhibitory effects of BNIP3
on melanoma cell migration and VM.
BNIP3 is required to maintain CD47 expression levels.
Cdc42 and Rac1 have been shown to be activated down-
stream of CD47(cluster of differentiation 4),45,46 a ubiqui-
tously expressed integrin-associated protein CD47, which
has been shown to physically interact with a pool of BNIP3 in
T lymphocytes.47 Remarkably, as judged by western blotting,
the protein levels of CD47 were significantly reduced in
BNIP3-shRNA expressing melanoma cells (by 67%) as
compared with control cells (Figure 7a). In contrast, exposure
of wild-type B16-F10 cells to hypoxia, a known inducer of
HIF-1-driven BNIP3 expression (Figure 7b) increased CD47
levels, thus providing evidence for the existence of a tight
crosstalk between these proteins. Note that the anti-CD47
antibody used recognizes different bands ranging from
35 kDa (predicted molecular weight) to 50 kDa (Figures 7a
and b), which have been observed by other groups before
and probably correspond to different N-glycosylated forms of
CD47, as reported previously.48
Along with CD47, BNIP3 KD reduced the protein levels
of the adherens junction protein VE–cadherin and the tight
junction protein ZO-1 (Figure 7c), as also evidenced by
the reduction in ZO-1 foci in BNIP3-silenced cells by
immunocytochemistry (Figure 7d). This finding is interesting
since CD47 was found to be localized at cell–cell adhesion
sites in a complex with cadherins and ZO-1 in epithelial
cells.49 Since the interaction of CD47 with BNIP3 was
reported to spare BNIP3 from proteasomal degradation,50
we tested whether this process was bi-directional. The
addition of the inhibitor of the proteasome MG132 to BNIP3-
shRNA cells led to a reestablishment in CD47 protein levels
(Figure 7e), suggesting that increased proteasomal degradation
of CD47 occurs in BNIP3-silenced cells. Moreover, blockage
of V-ATPase-driven endosomal/lysosomal acidification by
CTL BNIP3 KD
Integrin αV
3.601.00 1.581.00
P-FAK
CTL BNIP3 KD
Vinculin
2.031.00
CTL BNIP3 KD
CTL BNIP3 KD
IntegrinαV
Phalloidin
DAPI
Integrin αV
DAPI
IntegrinαV
Phalloidin
DAPI
Integrin αV
DAPI
P-FAK
Phalloidin
DAPI
P-FAK
DAPI
P-FAK
Phalloidin
DAPI
P-FAK
DAPI
CTL BNIP3 KD
vinculin
Phalloidin
DAPI
vinculin
DAPI
vinculin
Phalloidin
DAPI
vinculin
DAPI
CTL BNIP3 KD
Actin Actin Actin
Figure 5 BNIP3 is essential to maintain balanced FAs. (a–c) Analysis of the protein levels of integrin (a), P-FAK (b) and vinculin (c) of B16-F10 cells (24 h after cell plating)
using immunoblotting, a representative western blot (n¼ 3) and quantifications of control and BNIP3 KD samples is shown, actin is used to verify equal loading.
(d) Representative confocal images (n¼ 3, five pictures per condition) of control and BNIP3 KD B16-F10 cells (24 h after cell plating), after immunostaining for integrin av and
incubation with Phalloidin-Rhodamine, scale bars represent 10mM. (e) Representative confocal images (n¼ 3, five pictures per condition) of control and BNIP3 KD B16-F10
cells (24 h after cell plating), after immunostaining for P-FAK and incubation with Phalloidin-Rhodamine, scale bars represent 10 mM. (f) Representative confocal images
(n¼ 3, five pictures per condition) of control and BNIP3 KD cells (24 h after cell plating), after immunostaining for vinculin and incubation with Phalloidin-Rhodamine, scale bars
represent 10mM
BNIP3 controls melanoma cytoskeleton organization
H Maes et al
6
Cell Death and Disease
Bafilomycin A1, also rescued CD47 levels in BNIP3-knocked
down cells (Figure 7e), thus implying that while basal
CD47 turnover in melanoma cells is relatively slow, loss of
BNIP3 might also stimulates the lysosomal degradation of
CD47.
Altogether, these findings reveal that in B16-F10melanoma
cells, maintenance of the steady-state levels of CD47, at least
in part, requires the presence of BNIP3.
Since the tight association between BNIP3–CD47 levels
in melanoma cells was unprecedented, we performed a
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Representative western blots of the bead-bound fraction and total cell lysate (not corrected for protein concentration) probed with Rac1 antibody (n¼ 4) or Cdc42 antibody
(n¼ 3) are shown. (c) Two-dimensional cell migration of control versus Rac inhibitor (EHop-016; 1 mM-24 h) and/or Cdc42 inhibitor (ML-141; 2mM-24 h) treated cells.
Representative images (n¼ 3) of the scratch wound at time point 0 h, 18 h and zoom of 18 h and quantification of the wound area (size wound at Tx/size wound at T0) are
shown. Arrows indicate the wound area, scale bars represent 800mm. (d) The ability of the B16-F10 cells to form a vascular-like network was assessed by plating the cells
on growth factor reduced Matrigel (16 h after cell plating). Representative images (n¼ 4) and quantification are shown of control versus Rac inhibitor (EHop-016; 1mM-16 h)
and/or Cdc42 inhibitor (ML-141; 2 mM-16 h) treated cells, scale bars represent 200mm
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correlation analysis of transcript-level expression for BNIP3
and CD47 on a cohort of skin cutaneous melanoma patients
(available from the Tumor Cancer Genome Atlas (TCGA) –
http://cancergenome.nih.gov). This analysis revealed that
BNIP3 and CD47 transcript levels indeed correlated signifi-
cantly with each other for this cohort (Figure 7f, ***Po0.0001).
The correlation coefficient value for this analysis (0.28, with a
95% confidence interval of 0.17–0.38) and the significantly
small P-value, suggest that clinical correlation between the
levels of BNIP3 and CD47 transcripts is not due to random
sampling (Figure 7f). In all these data underscore the
existence of a close link between BNIP3 and CD47, which
may be of clinical relevance in melanoma.
Discussion
Actin cytoskeleton remodeling, which is tightly controlled by
intracellular signaling complexes, does not only affect cell
motility, hereby supporting migration, invasion and metastatic
spreading, but also other vital cellular processes associated
with cancer cell survival and aggressiveness and therefore
constitutes a crucial aspect of tumor progression.
In this study, we show for the first time that altering baseline
BNIP3 expression in melanoma cells causes aberrations in
the actin cytoskeletal organization, thereby impairing
hallmarks of aggressive tumors, like migration and VM. First,
we show that BNIP3 in melanoma helps controlling redox
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Figure 7 BNIP3 KD reduces the protein levels of CD47, associated with reduced cell–cell interaction. (a) Analysis of the effect of BNIP3 KD B16-F10 cells on CD47 protein
level (24 h after cell plating). A representative western blot (n¼ 6) probed with anti-CD47 antibody of control and BNIP3 KD cells is shown. Actin is used as a loading control.
(b) Analysis of the effect of hypoxia (1.5%O2-24 h)-induced BNIP3 on CD47 protein level as compared with BNIP3 KD (24 h after cell plating). A representative western blot
(n¼ 3) probed with anti-CD47 antibody of EV normoxia, EV hypoxia and BNIP3 KD B16-F10 cells (normoxia) is shown, actin is used to verify equal loading. Note that the
baseline levels of BNIP3 in this western blot are almost not visible due to lower exposure chosen to avoid overexposure of the signal of the hypoxia-mediated BNIP3 induction.
(c) Immunoblotting for the adherens junction protein VE–cadherin and the tight junction protein ZO-1 (24 h after cell plating) of B16-F10 cells, actin is used to verify equal
loading (n¼ 3). (d) Confocal microscopy analysis after immunostaining for ZO-1 to reveal tight junctions and Phalloidin-Alexa 488 to document cellular orientation combined
with the nuclear dye DAPI of B16-F10 cells (24 h after cell plating). Representative pictures (n¼ 3) of control and BNIP3 KD cells are shown, scale bar represents 10 mM.
(e) Effect of proteasome inhibition via MG132 10mM-3 h (MG132) or inhibition of lysosomal degradation via Bafilomycin A1 10 nM-3 h (BAF) on CD47 protein levels in control
and BNIP3 KD B16-F10 cells. Quantification of immunoblots (n¼ 4) probed with anti-CD47 antibody of control and BNIP3 KD cells treated with DMSO, LAC and BAF (relative
to DMSO-treated control conditions) are shown, actin is used to verify equal loading. (f) A scatterplot of correlation between CD47 transcript expression levels and BNIP3
transcript expression levels in a cohort of skin cutaneous melanoma patients (n¼ 312). Correlation levels have been estimated on the basis of correlation coefficient
(Corr. Coef.) and the P-value for this correlation (PCorr), both of which are displayed on the plot. Here, a Corr. Coef.¼ 1 represents a perfect correlation between the variables
while Corr. Coef. between 0 and 1 denotes that the two variables tend to increase or decrease together
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status compatible with cell viability, most likely by removing
the excess of ROS-producing mitochondria, since silencing
BNIP3 expression provokes an increase in the amount of
ROS and doubles mitochondrial mass. This BNIP3-mediated
effect is associated with a reduced cancer cell migratory
behavior and with a complete failure to form vasculature-like
structures. This is rather striking, considering that recent
studies have linked increased mitochondrial ROS to stimula-
tion of cancer cell proliferation and motility.51,52 Moreover,
RhoA, a member of the Rho family of GTPases, critical
regulators of cell migration and adhesion, can be directly
activated by ROS or modulated by a ROS-mediated
stabilization of HIF-1.25 However, our data do not confute
the positive role of ROS signaling in cancer cell motility and
proliferation. They rather suggest that loss of BNIP3 affects
migration and abolishes VM by modulating additional
mechanisms, which may counterbalance the effects of
increased ROS signaling on these processes, as discussed
below.
Second, we show that loss of BNIP3 causes profound
morphological alterations of melanoma cells coupled with
striking changes in the dynamic organization of the actin
filaments, required to form lamellipodia and filopodia, driving
cell migration. These BNIP3-mediated effects are not
phenocopied by Atg5-KD, thus separating them from the
pro-autophagic activity of BNIP3.
This study rather reveals that BNIP3 modulates important
functions of CD47-mediated intracellular signaling. BNIP3
silencing reduced CD47 protein levels, whereas a physiolo-
gically relevant increase in BNIP3 protein levels, induced by
hypoxia, augmented CD47 protein levels in melanoma cells.
Moreover, we found that a strong correlation exists between
CD47 and BNIP3 transcript levels in a clinical cohort of
melanoma. CD47 is a membrane receptor for thrombospodin
(TSP) family members, known to stimulate integrin-mediated
adhesion of different cells, including melanoma,53 migration
and lamellipodia formation49 and to indirectly interact with
FAK.54 Here we show that BNIP3 silencing alters CD47-
modulated intracellular complexes regulating cytoskeletal
dynamics, like Cdc42 and Rac1, members of the Rho-
GTPases orchestrating cell spreading and movements. In
line with this, adhesion and cell spreading on vitronectin
substratum of C32 melanoma were stimulated by CD47
expression.55 The downregulation of two CD47 targets,
Cdc42 and Rac1, in BNIP3-silenced cells is in line with the
impairment in the formation of protrusions of lamellipodia and
filopodia, observed in these less motile melanoma cells.
Indeed, these BNIP3-mediated effects are phenocopied to a
large extent by the combined inhibition of Cdc42 and Rac1,
which results in reduced cell migration and abolishment of the
VM phenotype.
On the other hand, the persistence of bundles of actin
stress fibers and elevated integrin-P-FAK complexes in
BNIP3-shRNA expressing cells suggest that disturbing BNIP3
function unbalances the spatio-temporal dynamics of multiple
Rho GTPase family members, resulting in a unique actin
cytoskeletal phenotype. A reciprocal and redox-modulated
inhibitory relationship between Rac and Rho GTPases
controlling cell movement behaviors has been described in
different cancer cells.56 Thus, downregulation of Rac1 and
Cdc42 by BNIP3 KD may result in increased Rho activation,
leading to the morphological persistence of stress fibers and
FA complex assembly in BNIP3-silenced cells. Irrespective of
the complex crosstalk between RhoGTPase family members,
which requires further studies, the loss of clonogenic survival
and abolishment of VM phenotype caused by loss of BNIP3 in
melanoma cells, indicate that rather than affecting a particular
mode of motility, BNIP3 modulates essential processes
supporting cancer cell survival and spreading. Increasing
evidence suggests that in the growing tumor, aggressive
cancer cells can participate in the de novo formation of a
functional vascular network, by acquiring an endothelial-like
phenotype that enables them to form perfused channels and
tubular structures resembling blood vessels in tumors, a
process referred to as VM.23,57 Although the molecular
mechanisms underlying the VM phenotype are not completely
understood, this process is stimulated by hypoxia signaling
and requires productive cell migration.23,57 So far, no reports
have associated VM with BNIP3 but based on our results, it is
tempting to speculate that the down-modulation of the CD47
intracellular signaling, alongwith the significant changes in the
adherent and migratory features of the BNIP3-silenced
cancer cells, are crucially linked to the eradication of VM.
Previous work in lymphocytes disclosed that CD47 physi-
cally interacts with BNIP3 through the multiple membrane
spanning domain of CD47 and the transmembrane domain of
BNIP3. This interaction was reported to prevent BNIP3
proteasomal degradation.47 BNIP3 function in T cells was
pro-death, and required binding of the CD47 ligand TSP-1.47
Our results in melanoma cells demonstrate that BNIP3 has
overall pro-survival functions, including the modulation of
melanoma adhesion and migration, which could be regulated
also through its binding to CD47. Loss of BNIP3 results in the
down-modulation of CD47 expression levels, which can be
mitigated by the inhibition of the proteasome with MG132 or
the vacuolar-type Hþ -ATPase with Bafilomycin A1. This
suggests that disruption of the BNIP3–CD47 complex favors
degradation of CD47, through mechanisms that still remain to
be identified in future studies.
Intriguingly, changes in pathways governing the cytoskele-
tal and actin dynamics are a prominent feature of the
proteome of aggressive human melanoma58,59 and CD47
levels are increased in clinical samples of melanoma
patients.60 In line with this, CD47 silencing60 or targeting the
actin cytoskeleton by a novel class of anti-tropomyosin
compounds,61 resulted in an effective strategy reducing
B16-F10 melanoma growth in vivo. Interestingly, a retro-
spective meta-analysis of publically available clinical cohorts
suggests that BNIP3 transcript-expression levels tend to
correlate with reduced overall survival in patient cohorts of
various solid tumor types like breast cancer, ovarian cancer,
colorectal cancer and glioma (data not shown). Such a trend is
also suggested by the analysis of melanoma patient cohort;
however, it was not found significant due to issues related to
expression-based stratification in this only publically available
melanoma cohort (data not shown). In future, it would be
necessary to ascertain whether this correlation between
BNIP3–CD47 levels is confirmed in larger, better stratified
melanoma patient cohorts and whether it also exists on a
protein level – as advocated in the current study.
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In conclusion, the role of BNIP3 in the maintenance of
cytoskeletal organization andmigration described in our study
may be a key mechanism favoring a melanoma metastatic
phenotype. Moreover, since CD47 is one of the few well-
established ‘don’t-eat-me’ signals62 that may enable cancer
cells to escape phagocytosis by innate immune cells,63 our
study implicates that loss of BNIP3 by reducing CD47 levels
may enhance engulfment of melanoma cells and possibly
reduce its evasion from phagocytic immunosurvelliance,62 an
outstanding facet of this study that is currently under
investigation in our laboratory.
In conclusion, our findings unravel that BNIP3 has a pro-
survival and tumor promoting role in melanoma through its
novel function in the dynamic re-organization of the actin
cytoskeleton.
Materials and Methods
Cell culture and chemicals. Murine melanoma cells (B16-F10) were
maintained in RPMI containing 10% FBS, 2 mM glutamine and Penicillin
(1000 units/ml)/Streptomycin (0.1 mg/ml) (cell culture reagents were from Sigma-
Aldrich, Bornem, Belgium, unless mentioned otherwise). All cells were routinely
maintained in 5% CO2 and 95% air at 37 1C. Human umbilical vein endothelial
cells (HUVEC) were a kind gift from Dr. P. Carmeliet (Vesalius Research Center,
VIB/KU Leuven) and were cultured in EGM2 bullet kit medium (Lonza, Verviers,
Belgium). All chemicals were obtained from Sigma-Aldrich, unless mentioned
otherwise. For hypoxic conditions the cells were kept in an Invivo2 400 hypoxia
workstation from Ruskinn (1.5% O2, 5% CO2, 93.5% N2), (Heusden-Zolder,
Belgium).
Determination of cell death and colony formation. Cell death was
determined by PI exclusion. Briefly, cells were trypsinized at the indicated time
points and incubated with the vital dye PI. PI-positive (dead) cells were quantified
via flow cytometry (Attune Cytometer, Invitrogen, Life Technologies, Paris,
France). For the colony formation assay, cells were plated as single cell
suspension at very low density (500 cells in 15ml medium on a 10 cm dish). After
growth for 7 days, cells were fixed in methanol containing 1% methylene blue and
imaged using a Leica DC200 camera.
Determination of mitochondrial mass. Mitochondrial DNA content was
assessed after the extraction of total DNA content using PureLink genomic DNA
mini kit from Invitrogen (Merelbeke, Belgium) by determining mitochondrial DNA
copy number (lipoprotein lipase (LPL)) normalized to nuclear DNA copy number
(NADH dehydrogenase subunit 1 (ND1)) using RT-PCR. Mitochondrial staining
was detected after incubation of the cells with 25 nM Mitotracker Deep Red
(Molecular probes, Invitrogen, Merelbeke, Belgium) 30min at 37 1C. Fluorescence
was measured using a flow Cytometer (Attune Cytometer, Invitrogen, Life
Technologies, Paris, France).
Immunoblot analysis. Protein extraction and immunoblot analysis were
performed using a modified Laemmli sample buffer (125mM Tris-HCl, pH 6.8
buffer containing 2% SDS and 20% glycerol) in the presence of protease and
phosphatase inhibitors (Roche, Vilvoorde, Belgium). Lysates were separated by
SDS-PAGE under reducing conditions, transferred to a nitrocellulose or PVDF
membrane, and analyzed by immunoblotting. Primary antibodies used were anti-
LC3 and anti-BNIP3 from Cell Signaling (Leiden, The Netherlands), anti-VE-
cadherin from R&D Systems (Abingdon, UK), anti-phospho-FAK from BD-
Transduction Laboratories (Ermebodegem, Belgium), anti-ZO-1 from Invitrogen,
anti-Vinculin and anti-Integrin from Millipore (Merck, Overijse, Belgium), anti-Actin,
anti-Vinculin and anti-Vimentin from Sigma (Diegem, Belgium). Equal loading was
verified by actin immunostaining. Appropriate secondary antibodies were from
Thermo Scientific (Erembodegem, Belgium). The LICOR Odyssey System
(Westburg, Leusden, The Netherlands) was used for western blot detection
according to the manufacturer’s instructions. Quantifications were performed using
the Odyssey System software. Representative blots of at least three independent
experiments are shown.
Generation of shRNA stable clones of B16-F10 and A375m
cells. All the TRC1 shRNA clones were in lentiviral pLKO.1-puro vector (Sigma-
Aldrich, St. Louis, MO, USA) and were obtained from the BCCM/LMBP Plasmid
collection, Department of Biomedical Molecular Biology, Ghent University, Belgium
(http://bccm.belspo.be/about/lmbp.php). An empty pLKO.1-puro control vector was
used as a control (CTL) (BCCM/LMBP Plasmid collection). Three shRNAs
targeted against the murine mRNA coding for the proteins Atg5 (NM_053069;
NM_053069; NM_053069) and BNIP3 (NM_009760; NM_009760; NM_009760)
and for the human BNIP3 (NM_004052.2–800s1c1; NM_004052.2-226s1c1;
NM_004052.2-184s1c1) were used. The sequences resulting in the best KD
(available upon request) compatible with cell viability were used for further
experiments. To generate lentiviral particles, HEK 293T cells were seeded in
25 cm2 flasks at 1.3 106 cells per 4ml and transfected the following day by the
calcium phosphate method with 4mg of pLKO.1-puro carrying the respective
shRNAs or with empty pLKO.1-puro. Each transfection also included 1.2 mg of a
plasmid encoding VSV-G (pMD2-VSV-G, Tronolab) and 2.6 mg of a plasmid
encoding packaging proteins (pCMVdR8.9, Tronolab). After 6 h, the cells are
washed with prewarmed PBS and 4ml of fresh media was added. Twenty-four
hours after transfection, the cells were placed at 37 1C for another 24 h. VSV-G
pseudotyped virus was collected 48 h after transfection, passed through 0.45mm
filters and then added to the exponentially growing B16-F10 or A375m cell cultures
in the presence of 8mg/ml of polybrene. Seven hours later, a second infection was
done. The cells were expanded and selected by puromycin treatment (9 mg/ml) for
3 days. KD of ATG5 and BNIP3 was confirmed by immunoblotting.
Scratch wound and tube formation assays. A scratch wound was
applied on the confluent melanoma monolayer using a 200ml tip. After scratch
wounding cultures were further incubated in the presence of Mitomycin C and
photographed at the indicated time periods. Wound closure (gap area at Tx/gap
area at T0) was measured with NIH ImageJ software. To assess tube formation
melanoma cells were seeded on growth factor reduced BD Matrigel (BD
biosciences, Erembodegem, Belgium), after overnight incubation pictures were
taken and analyzed.
Determination of ROS production. ROS levels were detected after
incubation of the cells with 7.5mM CM-H2DCFDA (Molecular probes, Invitrogen,
Merelbeke, Belgium) 30min at 37 1C. Fluorescence was measured using a flow
Cytometer (Attune Cytometer, Invitrogen, Life Technologies, Paris, France).
Similar assays were run to ascertain the scavenging effects of antioxidants, like
NAC on ROS levels.
Immunostaining. After fixation for 20min in 4% paraformaldehyde at 37 1C,
cells were permeabilized for 15min in 1% Triton-X and subsequently blocked in
5% goat serum for 1 h. After incubation with the appropriate primary (overnight
incubation at 4 1C) and secondary (2 h at room temperature) antibodies, the cells
were imaged using a Nikon confocal microscope.
Correlation analysis of transcripts in a clinical cohort. For
correlation analysis of transcript-level expression for BNIP3 and CD47, exon
expression profile measured experimentally using the Illumina HiSeq 2000 RNA
Sequencing platform in 312 patients of skin cutaneous melanoma was
downloaded along with the clinical matrix using the UCSC Cancer Genomics
Browser (http://genome-cancer.ucsc.edu).64,65 The expression profile (level 3)
data set basically consisted of exon-level transcription estimates in RPKM values
(Reads per kilobase of exon model per million mapped reads). The values for
BNIP3 (chr10 : 133795265-133795435) and CD47 (chr3 : 107809710-107809935)
were then manually extracted from this data set and a XY scatter plot was created
using the GraphPad Prism 5 software. Statistical analysis consisted of a non-
parametric correlation analysis (Spearman) performed on this data with two-tailed
P-value expected and confidence interval set at 95%.
Statistical analysis. Statistical significance, unless otherwise mentioned,
was assessed by Student’s t-test (two-tailed distribution, two-sample, unequal
variance), *Po0.05, **Po0.001, ***Po0.0001.
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